Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030193 (pain)
 261,466 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In a comparative study Progestasert and Copper-T-200 were tested. Progestasert had a significantly higher expulsion rate and required removal due to bleeding, pain or medical reasons. As a consequence, 12 months after insertion the continuation rate of Progestasert was only 66.3% in comparison with 90.4% with Copper-T-200.
 ...
PMID:[A comparative study of the clinical effectiveness of Progestasert and Copper-T-200 (author's transl)]. 693 39

Skin conductance and heart rate measures obtained from subjects previous to, during, and after their performance of the cold pressor task were correlated with their responses to the McGill Pain Questionnaire administered immediately after the completion of the cold pressor task. A reliable relationship between skin conductance level and responses on the evaluative scale of the MPA was found in the resting state, while anticipating the cold pressor task and during this task. Heart rate was related to these pain reports only during the warning or anticipation period. These findings were interpreted as supporting the use of the McGill Pain Questionnaire in the assessment of the reactive component of pain. They also suggest the utility of further research into autonomic indices as physiological correlates of this reactive aspect of pain.
Pain 1982
PMID:Autonomic indices and reactive pain reports on the McGill Pain Questionnaire. 716 40

A 42-year-old woman was administered a cleansing enema to treat chronic constipation. Immediately after the procedure she developed intense pain in the abdominal region, nausea, vomiting, and rectal bleeding. The patient, who was in good general health, had been on contraceptive administration of Depo-Provera (150 mg each month) for 1 year. Radiological investigation, endoscopy and histopathological examinations revealed acute ischemic colitis. A left hemicolectomy was performed with colorectal anastomosis through laparotomy; the postoperative period was good and the patient was discharged in good health. The majority of cases of ischemic colitis occur in persons of advanced age, because of arteriosclerosis. In young female patients it is necessary to systematically investigate contraceptive use as a possible iatrogenic cause; surgery may be indicated in some cases.
 ...
PMID:Ischemic colitis attributable to a cleansing enema. 725 Sep

Today, hysterectomy internationally is nearly as frequent as appendectomy. In approx. 1% of all hysterectomies (vaginal or abdominal) where one or both ovaries are left, the residual ovary syndrome is found after an average period of slightly over five years. Predominant symptoms are diffused abdominal pain and palpable tumour of the adnexae. More rarely, only one symptom alone is found. Up to today, treatment of choice has been an operation which, due to the always present adhesions, is a severe one. The results described in this paper suggest the probatory treatment with high-dosage dept-gestagens (Depo-Provera). In 71% of the cases the tumour disappeared completely under this treatment and in 39% the pain. In further 21% a diminution of the tumour could be seen and in 41% an improvement of the pain. Only in 8% did the tumour and in 20% the pain not respond. There was no case where there was a deterioration. The proposed therapy is cheaper and less dangerous than the usual surgical treatment and therefore should always be performed probatorily before an operation.
 ...
PMID:[Residual ovary syndrome--significance of medical therapy (author's transl)]. 735 70

Phase 3 clinical trials (carried out during 1972-1976) of the Progestasert IUD system are reported. In addition, reinsertion was made 1 year later, and side effects associated with both the initial and reinsertion are reported and compared. Reinsertion did not interrupt the stabilizing or declining trends in incidences of pelvic inflammatory disease, removals for bleeding/pain, removals for other medical indications, or removals for pregnancies. In addition, reinsertion did not affect trends pertaining to moderate/severe menstrual cramps/bleeding or premenstrual/intermenstrual cramping incidence. Incidence of pelvic inflammatory disease, when this series is compared with data for the U.S., was not increased among users of the Progestasert IUD system. However after reinsertion, the incidences of expulsions and intermenstrual spotting and bleeding did rise temporarily to about half their previous peaks with initial insertion, but they diminished markedly within 2 months of reinsertion and reverted to levels and favorable patterns of change which had been established during the first year of IUD use.
 ...
PMID:Selected events following insertion of the Progestasert system. 742 59

The capability of an early second injection or prior use of oral contraceptives (OCs) to improve satisfaction and long-term continuation of Depo-Provera in adolescents was investigated in a clinical trial involving 78 females 12-20 years of age (average, 15.9 years) recruited from a hospital-based adolescent health clinic. 36 subjects received injection of 150 mg of Depo-Provera every three months (Group 1), 27 received the second injection after only six weeks (Group 2), and 15 switched directly from OCs to the standard Depo-Provera regimen (Group 3). There was no difference between Groups 1 and 2 in terms of duration or frequency of menstrual bleeding; however, prior OC users experienced a significant reduction in the duration and intensity of bleeding in the first six months of Depo-Provera use (when estrogen was still present in the women's systems). Overall, 64% of study subjects reported less dysmenorrhea while on Depo-Provera. A slightly greater change in body mass index was observed among girls in Group 2 than in Groups 1 and 3; moreover, 70% of those in the early injection group reported increased appetite and weight gain compared to 39% of those on the standard schedule. The most commonly reported side effects included initial pain and soreness at the injection site (27%), decreased libido (56%), mood changes (31%), depression (26%), frequent headache (25%), fatigue (24%), and increase in acne (15%); there were no significant differences by group. 17 adolescents (22%) discontinued Depo-Provera, generally after two injections and due to bleeding irregularities or weight gain. 87% of adolescents who were prior OC users, 52% of those on the regular schedule, and 39% of those who received an early injection stated they were very satisfied with Depo-Provera. These findings indicate that early second Depo-Provera injection offers no advantages; use of OCs immediately prior to Depo-Provera should be further investigated, however, given its potential to minimize bleeding problems.
 ...
PMID:Depo-Provera in adolescents: effects of early second injection or prior oral contraception. 766 88

Progestin-releasing IUDs have been developed to combine the advantages of hormonal and intrauterine contraception. Oral contraceptives are known to be effective, to favorably affect bleeding patterns and menstrual pain, and to give some protection against pelvic infection. On the other hand, IUDs are long-acting and do not require daily motivation by the user to be effective. Two progestin-releasing IUDs are commercially-available, Progestasert and Levonoa. The progesterone-releasing IUD Progestasert was introduced in the US as early as 1976, while the levonorgestrel-releasing IUD Levonoa was introduced in Finland in 1990. The latter device has only been recently released and is therefore not widely available. The devices are different from each other as far as their clinical performance and effective lifetimes are concerned. The author describes the devices and potential acceptors, then discusses when the devices should be fitted, clinical management, problems and benefits, and special counseling requirements.
 ...
PMID:Progestin-releasing intrauterine devices. 770 26

Systemic therapy, pain relief and the quality of life (QOL) of breast cancer patients with bone metastasis were described. QOL was measured using a "QOL questionnaire" developed by the Ministry of Welfare in Japan. It was proved objectively that QOL scores in the cases with bone metastasis were significantly low in terms of activity, physical psychological conditions. Chemoendocrine therapy, endocrine therapy and outpatient therapy showed a high QOL score. The cases with bone pain showed a low QOL scores. In the 45 cases whose first metastatic site was bone only, there were no differences between endocrine therapy and chemoendocrine therapy in the rate and period of response or the total QOL score. MPA showed a higher response rate and a higher pain relief rate than TAM. In the cases with bone metastasis but without severe visceral metastasis, MPA monotherapy showed an excellent response when the tumor was ER or PgR positive, or when there was a long disease-free interval of more than three years, or if there was no previous therapy. MPA monotherapy is a suitable firstline therapy in such cases. Radiation therapy was more effective for bone pain (response rate 96.3%), and it was also effective in cases in which systemic therapy was not.
 ...
PMID:[Systemic therapy, pain relief and quality of life of breast cancer patients with bone metastasis]. 774 85

More than 25% of postmenopausal women are at risk of osteoporosis. In order to avoid its consequences, it is necessary to find an appropriate prevention and/or treatment. We studied: (1) 15 postmenopausal women treated with percutaneous estradiol (50 micrograms/24 h) plus MPA (10 mg/10 days/month); (2) 15 postmenopausal women treated with synthetic calcitonin nasal spray at the daily dose of 100 IU; (3) 10 postmenopausal women treated with nandrolone decanoate (50 mg every 3 weeks); (4) 10 postmenopausal women treated with ipriflavone (600 mg/day); and (5) 10 postmenopausal women treated with sodium fluoride (20 mg) plus calcium (600 mg). Clinical examination, bone mass measurement (total BMD), hematochemical and urinary parameters of bone metabolism (calcium, urinary hydroxyproline, PTH) and growth factors (as IGF-I and TNF-beta) were evaluated. After 6 months of therapy, a complete prevention of bone resorption was achieved. In agreement with current literature, we observed that the various therapeutic approaches have all some positive effect on BMD, with different results on pain, blood biochemical parameters and growth factors' concentrations.
 ...
PMID:Management of postmenopausal osteoporosis. 798 17

Intra-articularly administered, long-acting corticosteroids are a beneficial treatment for many equine joint disorders because they alleviate inflammation and signs of pain, but they also exert detrimental effects on the biochemical composition and morphologic features of articular cartilage. Chondroprotective drugs have been shown to mitigate some of the deleterious effects of intra-articularly administered corticosteroids on articular cartilage of laboratory animals. Twenty-one ponies were assigned at random to receive 1 of 3 treatments in the right middle carpal joint. Group-1 ponies (n = 8) had methylprednisolone acetate (MPA; 0.2 mg/kg of body weight) and saline solution administered intra-articularly and IM, respectively. Group-2 ponies (n = 9) received MPA (0.2 mg/kg) and polysulfated glycosaminoglycan (GAG; 2 mg/kg). Group-3 ponies (control; n = 4) had saline solution administered intra-articularly and IM. The corticosteroid or saline solution was injected into the right middle carpal joint on day 1. The IM administered polysulfated GAG or saline solution was administered at the same time, then was repeated every 3 days for 20 days. Ponies were euthanatized 21 days after initial injection by overdose of pentobarbital sodium. The cartilage of younger ponies was significantly (P < 0.05) more responsive to the proteoglycan-depleting effects of MPA. Ponies < 10 years old of groups 1 and 2 had significantly (P < 0.05) lower GAG content in the articular cartilage than did control ponies. Systemic treatment with polysulfated GAG did not result in a protective effect against proteoglycan loss from the articular cartilage.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Effect of intramuscularly administered polysulfated glycosaminoglycan on articular cartilage from equine joints injected with methylprednisolone acetate. 821 10


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>